San Diego, CA, USA, and Munich, Germany – October 21, 2025 – selectION, Inc. (“selectION” or the “Company”), a clinical-stage biopharmaceutical company developing novel treatments for T cell-mediated autoimmune diseases, today announced the successful completion of its phase 1b proof-of-concept trial evaluating si-544, a first-in-class Kv1.3 blocker in patients diagnosed with psoriasis vulgaris.

His groundbreaking work on T cells and immune regulation has paved the way for innovative immunotherapies, offering new hope to millions of patients living with autoimmune and inflammatory diseases. Dr. Ramsdell’s…

New study follows completion of first-in-human Phase 1b trial in atopic dermatitis patients, in which selectION observed safety and tolerability of si-544 in the treatment of T cell autoimmunity Recruitment…

si-544 was well tolerated with no serious adverse effects, dose limiting toxicities, or safety signals observed 75% of patients receiving si-544 experienced objective clinical improvement, of which 44% achieved clear…